5 results on '"Silveira, Fernanda P."'
Number of results to display per page
Search Results
2. COVID-19 after two doses of mRNA vaccines in kidney transplant recipients
- Author
-
Mehta, Rajil B. and Silveira, Fernanda P.
- Published
- 2021
- Full Text
- View/download PDF
3. A consensus conference to define the utility of advanced infectious disease diagnostics in solid organ transplant recipients
- Author
-
Azar, Marwan M., Turbett, Sarah, Gaston, David, Gitman, Melissa, Razonable, Raymund, Koo, Sophia, Hanson, Kimberly, Kotton, Camille, Silveira, Fernanda, Banach, David B., Basu, Sankha S., Bhaskaran, Archana, Danziger-Isakov, Lara, Bard, Jennifer Dien, Gandhi, Ronak, Hanisch, Benjamin, John, Teny M., Odom John, Audrey R., Letourneau, Alyssa R., Luong, Me-Linh, Maron, Gabriela, Miller, Steve, Prinzi, Andrea, Schwartz, Ilan, Simner, Patricia, and Kumar, Deepali
- Abstract
The last decade has seen an explosion of advanced assays for the diagnosis of infectious diseases, yet evidence-based recommendations to inform their optimal use in the care of transplant recipients are lacking. A consensus conference sponsored by the American Society of Transplantation (AST) was convened on December 7, 2021, to define the utility of novel infectious disease diagnostics in organ transplant recipients. The conference represented a collaborative effort by experts in transplant infectious diseases, diagnostic stewardship, and clinical microbiology from centers across North America to evaluate current uses, unmet needs, and future directions for assays in 5 categories including (1) multiplex molecular assays, (2) rapid antimicrobial resistance detection methods, (3) pathogen-specific T-cell reactivity assays, (4) next-generation sequencing assays, and (5) mass spectrometry-based assays. Participants reviewed and appraised available literature, determined assay advantages and limitations, developed best practice guidance largely based on expert opinion for clinical use, and identified areas of future investigation in the setting of transplantation. In addition, attendees emphasized the need for well-designed studies to generate high-quality evidence needed to guide care, identified regulatory and financial barriers, and discussed the role of regulatory agencies in facilitating research and implementation of these assays. Findings and consensus statements are presented.
- Published
- 2022
- Full Text
- View/download PDF
4. HOPE in action: A prospective multicenter pilot study of liver transplantation from donors with HIV to recipients with HIV
- Author
-
Durand, Christine M., Florman, Sander, Motter, Jennifer D., Brown, Diane, Ostrander, Darin, Yu, Sile, Liang, Tao, Werbel, William A., Cameron, Andrew, Ottmann, Shane, Hamilton, James P., Redd, Andrew D., Bowring, Mary G., Eby, Yolanda, Fernandez, Reinaldo E., Doby, Brianna, Labo, Nazzarena, Whitby, Denise, Miley, Wendell, Friedman‐Moraco, Rachel, Turgeon, Nicole, Price, Jennifer C., Chin‐Hong, Peter, Stock, Peter, Stosor, Valentina, Kirchner, Varvara A., Pruett, Timothy, Wojciechowski, David, Elias, Nahel, Wolfe, Cameron, Quinn, Thomas C., Odim, Jonah, Morsheimer, Megan, Mehta, Sapna A., Rana, Meenakshi M., Huprikar, Shirish, Massie, Allan, Tobian, Aaron A. R., Segev, Dorry L., Pereira, Marcus, Piquant, Dominique, Edwards, Carolyn, Ranganna, Karthik M, Link, Katherine, Pearson, Thomas, Mehta, Aneesh K, Lyon, G. Marshall, Kitchens, William, Huckaby, Jeryl, Elbein, Rivka, Roberson, April, Ferry, Elizabeth, Adebiyi, Margaret, Adebiyi, Oluwafisayo, Kubal, Chandrahekhar, Ambinder, Richard, Barnaba, Brittany, Bismut, Gilad, Bollinger, Juli, Boyarsky, Brian, Charles, Curtisha, Cochran, Willa V, Desai, Niraj N, Doby, Brianna, Johnstone, Jaylyn, Kirby, Charles, Klock, Ethan, Kusemiju, Oyinkansola, Miller, Jernelle, Morrison, Michelle, Prizzi, Michelle, Schmidt, Haley, Rasmussen, Sarah, Sugarman, Jeremy, Seaman, Shanti, Thomas, Margret, Akhran, Aleya, Coakley, Margaret, Cooper, Matthew, Gilbert, Alexander, Stucke, Alyssa, Timpone, Joseph, Castillo‐Lugo, Jose A, Townsend, Melba, Haydel, Brandy M., Goudy, Leah, Gallon, Lorenzo, Dieter, Rebecca, Deterville, Cecilia, Klein, Elizabeth, Neumann, Henry, Weldon, Elaina P, Hand, Jonathan, Smith, Angela R, Blumberg, Emily A, Donaghy, Eileen, Dunn, Ty, Sawinski, Deirdre, Mall, Mark, Santos, Carlos A. Q, Basinger, Katherine, Locke, Jayme E, Mehta, Shikha, Mompoint‐Williams, Darnell, Gadzhyan, Janette, Schaenman, Joanna, Aslam, Saima, Mekeel, Kristin, Nguyen, Phirum, Chao, Ada, Kwan, Joanne, Rogers, Rodney, Srisengf, Tab, Apewokin, Senu, Harrison, Kathleen, Kramer, Samantha, Wilkinson, Rachel, Benamu, Esther, Spaggiari, Mario, Bruno, Kelly, Brogden, Gregory, Husson, Jennifer, Jeffery, Alicia, Marrazzo, Ilise D, Morris, Michele I, Munoz, Carlos, Simkins, Jacques, Farnsworth, Mary, Haidar, Ghady, Hughes Kramer, Kailey, Pakstis, Diana Lynn, Silveira, Fernanda, Baah, Whitney, Carlson, Emily, La Hoz, Ricardo M, Agarwal, Avinash, Doyle, Alden, Nagy, Jamie, Baldecchi, Mary, Brigle, Nathaniel, Gupta, Gaurav, Butkus‐Small, Catherine, Muthukumar, Thangamani, Malinis, Maricar, and Tomlin, Ricarda
- Abstract
Liver transplantation (LT) from donors‐with‐HIV to recipients‐with‐HIV (HIV D+/R+) is permitted under the HOPE Act. There are only three international single‐case reports of HIV D+/R+ LT, each with limited follow‐up. We performed a prospective multicenter pilot study comparing HIV D+/R+ to donors‐without‐HIV to recipients‐with‐HIV (HIV D−/R+) LT. We quantified patient survival, graft survival, rejection, serious adverse events (SAEs), human immunodeficiency virus (HIV) breakthrough, infections, and malignancies, using Cox and negative binomial regression with inverse probability of treatment weighting. Between March 2016–July 2019, there were 45 LTs (8 simultaneous liver‐kidney) at 9 centers: 24 HIV D+/R+, 21 HIV D−/R+ (10 D− were false‐positive). The median follow‐up time was 23 months. Median recipient CD4 was 287 cells/µL with 100% on antiretroviral therapy; 56% were hepatitis C virus (HCV)‐seropositive, 13% HCV‐viremic. Weighted 1‐year survival was 83.3% versus 100.0% in D+ versus D− groups (p= .04). There were no differences in one‐year graft survival (96.0% vs. 100.0%), rejection (10.8% vs. 18.2%), HIV breakthrough (8% vs. 10%), or SAEs (all p> .05). HIV D+/R+ had more opportunistic infections, infectious hospitalizations, and cancer. In this multicenter pilot study of HIV D+/R+ LT, patient and graft survival were better than historical cohorts, however, a potential increase in infections and cancer merits further investigation. A multicenter study of HIV+ donor to HIV+ recipient liver transplantation under the HOPE Act shows that patient and graft survival were better than historical cohorts, but the possible increased incidence of infections and cancer merits further investigation.
- Published
- 2022
- Full Text
- View/download PDF
5. Changing trends in mortality among solid organ transplant recipients hospitalized for COVID‐19 during the course of the pandemic
- Author
-
Heldman, Madeleine R., Kates, Olivia S., Safa, Kassem, Kotton, Camille N., Georgia, Sarah J., Steinbrink, Julie M., Alexander, Barbara D., Hemmersbach‐Miller, Marion, Blumberg, Emily A., Multani, Ashrit, Haydel, Brandy, La Hoz, Ricardo M., Moni, Lisset, Condor, Yesabeli, Flores, Sandra, Munoz, Carlos G., Guitierrez, Juan, Diaz, Esther I., Diaz, Daniela, Vianna, Rodrigo, Guerra, Giselle, Loebe, Matthias, Rakita, Robert M., Malinis, Maricar, Azar, Marwan M., Hemmige, Vagish, McCort, Margaret E., Chaudhry, Zohra S., Singh, Pooja P., Hughes Kramer, Kailey, Velioglu, Arzu, Yabu, Julie M., Morillis, Jose A., Mehta, Sapna A., Tanna, Sajal D., Ison, Michael G., Derenge, Ariella C., Duin, David, Maximin, Adrienne, Gilbert, Carlene, Goldman, Jason D., Lease, Erika D., Fisher, Cynthia E., Limaye, Ajit P., De la Cruz, Oveimar, Besharatian, Behdad D., Crespo, Maria, Tomic, Rade, Sehgal, Sameep, Weisshaar, Dana, Girgis, Reda, Lawrence, Cameron, Nelson, Joanna, Bennett, William, Leandro, Jennifer, Sait, Afrah, Rumore, Amy, West, Patricia, Jeng, Amy, Bajrovic, Valida, Bilgili, Erin P., Anderson‐Haag, Tracy, Nastase, Abigail, Badami, Abbas, Alvarez‐Garcia, Jesus, Bowman‐Anger, Lyndsey, Julien, Lovelyn, Ortiz‐Bautista, Carlos, Friedman‐Morocco, Rachel, Gajurel, Kiran, Cahuayme‐Zuniga, Lizbeth, Wakefield, Mark, Fung, Monica, Theodoropoulos, Nicole, Chuang, Sally T., Bhandaram, Srividya, Veroux, Massimiliano, Chopra, Bhavna, Florescu, Diana, Witteck, Danielle, Diaz, Daniela, Ripley, Kathryn, Saharia, Kapil, Akkina, Sanjeev, McCarty, Todd P., Webb, Ally, Arya, Akanksha, Vedula, Giridhar, El‐Amm, Jose‐Marie, Katherine Dokus, M., Narayanan, Arun, Cilene Leon Bueno de Camargo, Priscila, Ouseph, Rosemary, Breuckner, Andrew, Luk, Alfred, Aujayeb, Avinash, Ganger, Daniel, Keith, Douglas S., Meloni, Federica, Haidar, Ghady, Zapernick, Lori, Moraels, Megan, Goyal, Nitender, Sharma, Tanvi, Malhotra, Uma, Kuo, Alexander, Rossi, Ana P., Edwards, Angelina, Keller, Brian, Beneri, Christy, Derringer, Darby, Dominguez, Edward, Carlson, Elise, Hashim, Faris, Murad, Haris, Wilkens, Heinrike, Neumann, Henry, Gani, Imran, Kahwaji, Joseph, Popoola, Joyce, Michaels, Marian, Jakharia, Niyati, Puing, Alfredo, Motallebzadeh, Reza, Velagapudi, Ravi, Kapoor, Rajan, Allam, Sridhar, Silveira, Fernanda, Vora, Surabhi, Kelly, Ursala M., Reddy, Uttam, Dharnidharka, Vikas, Wadei, Hani, and Zurabi, Lominadze
- Abstract
Mortality among patients hospitalized for COVID‐19 has declined over the course of the pandemic. Mortality trends specifically in solid organ transplant recipients (SOTR) are unknown. Using data from a multicenter registry of SOTR hospitalized for COVID‐19, we compared 28‐day mortality between early 2020 (March 1, 2020–June 19, 2020) and late 2020 (June 20, 2020–December 31, 2020). Multivariable logistic regression was used to assess comorbidity‐adjusted mortality. Time period of diagnosis was available for 1435/1616 (88.8%) SOTR and 971/1435 (67.7%) were hospitalized: 571/753 (75.8%) in early 2020 and 402/682 (58.9%) in late 2020 (p < .001). Crude 28‐day mortality decreased between the early and late periods (112/571 [19.6%] vs. 55/402 [13.7%]) and remained lower in the late period even after adjusting for baseline comorbidities (aOR 0.67, 95% CI 0.46–0.98, p = .016). Between the early and late periods, the use of corticosteroids (≥6 mg dexamethasone/day) and remdesivir increased (62/571 [10.9%] vs. 243/402 [61.5%], p< .001 and 50/571 [8.8%] vs. 213/402 [52.2%], p < .001, respectively), and the use of hydroxychloroquine and IL‐6/IL‐6 receptor inhibitor decreased (329/571 [60.0%] vs. 4/492 [1.0%], p< .001 and 73/571 [12.8%] vs. 5/402 [1.2%], p< .001, respectively). Mortality among SOTR hospitalized for COVID‐19 declined between early and late 2020, consistent with trends reported in the general population. The mechanism(s) underlying improved survival require further study. Data from the pre‐vaccine era show declining mortality among solid organ transplant recipients hospitalized for COVID‐19 over the course of the pandemic. Kalil comments on page 12.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.